New Independent Research and Society Practice Guidelines Bring Rapid Growth for Cervilenz Inc.
Milestones in obstetrics and for the CerviLenz device are bringing rapid growth to Cervilenz Inc.
- (1888PressRelease) October 18, 2012 - The American College of Obstetricians and Gynecologists (ACOG) published a Practice Bulletin, "Prediction and Prevention of Preterm Birth," earlier this month. This publication outlines a new screening strategy for routine pregnancies to identify patients at high risk for preterm birth and enable life-saving treatment. Recent research proves that vaginal progesterone can prevent preterm birth in pregnant women with a prematurely short cervix, cutting their risk nearly in half. This breakthrough led to these new practice guidelines. Now, cervical length assessment is becoming part of routine prenatal care.
An independent study of the CerviLenz device, conducted by the University of Western Australia, confirmed its efficacy for cervical length screening, validating previous research. Published last week by the Journal of Maternal-Fetal and Neonatal Medicine, the authors concluded, "The availability of CerviLenz promises to be an exciting step forward in facilitating greater access to cervical length measurement and assessment of risk of preterm birth."
Chris D'Errico, an experienced sales executive, joined the company this week as Vice President of Sales. Chris will be expanding the sales team to capitalize on these milestones and build on early sales success. Chris has more than 15 years of experience in the medical device area with a focus in women's health and success in developing markets for new products. Most recently, Chris was the Director of Sales and Market Development at Biosphere Medical.
The company was founded in anticipation of cervical length screening being added to the list of routine prenatal tests. "We applaud ACOG for giving physicians guidance on this new preterm birth prevention strategy. About half of preterm births occur in pregnancies thought to be routine. CerviLenz will play a vital role in identifying the patients who can benefit from vaginal progesterone, and that's the key to reducing the rate of this devastating pregnancy outcome," said Dean Koch, President and CEO of Cervilenz Inc.
Chris adds, "The timing of another successful study validating CerviLenz as a screening tool is perfect. These important milestones create a very large market for CerviLenz here in the U.S. Building from our small, experienced team, I am confident that we can accelerate adoption of CerviLenz."
Publication of the ACOG Practice Bulletin follows similar guidelines on cervical length and progesterone recently released by the Society for Maternal-Fetal Medicine (SMFM) and the American College of Nurse-Midwives (ACNM) earlier this year. With all three professional societies providing recommendations, the time has come for universal cervical length screening. Existing technology cannot meet the need for millions of new cervical length measurements. CerviLenz solves that problem by making cervical length screening easy and cost effective in any healthcare setting during a routine prenatal visit.
About Cervilenz Inc.
Cervilenz Inc. manufactures and markets the CerviLenz® device- an innovative medical device that measures cervical length to help physicians identify and manage pregnant women at high risk for preterm birth. Dedicated to making a difference in the world of prematurity, Cervilenz Inc. donates a portion of revenue to charitable organizations that advance maternal and fetal health globally. Founded in 2008, the company headquarters is in Chagrin Falls, a suburb of Cleveland, Ohio. The CerviLenz device is cleared for sale in the U.S. and has its CE Mark and ISO 13485 Certification for international distribution. For more information, visit www.cervilenz.com or contact Melanie Sweeney, Vice President of Marketing (440.337.4253 or melanie ( @ ) cervilenz dot com) dot
About Preterm Birth
Preterm birth is a worldwide public health epidemic and the leading cause of infant death. Nearly 13 million babies are born preterm every year. In the United States, preterm birth affects 12% of pregnancies and its annual economic toll is $26.2 billion in health care and related costs.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam